The patent contains claims regarding beta-alanine compositions in many formulations, wherein the beta-alanine is not part of a dipeptide, polypeptide or oligopeptide and is in the form of a dietary supplement.
Esters or amides of beta-alanine, which are not part of a dipeptide, polypeptide or oligopeptide, may also be employed and additional active agents including carbohydrates, L-histidine, insulin and creatine, may also be present.
NAI CEO and Chairman of the Board Mark A LeDoux said the patent would reinforce the company’s intellectual property portfolio besides providing a boost to their CarnoSyn beta-alanine business.
"NAI has multiple valid patents that include claims covering human dietary supplements containing beta-alanine," LeDoux added.